Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,501.24
(
0.77%
)
US TECH 100
28,791.60
(
0.00%
)
Dow Jones
50,063.46
(
0.75%
)
Brent Oil
104.86
(
0.65%
)
Bitcoin
80,788.14
(
-0.33%
)
News Focus
News Focus
Post# of 257566
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122982
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mcbio post# 132484

Tuesday, 12/17/2013 7:45:24 PM

Tuesday, December 17, 2013 7:45:24 PM

Post# of 257566
BIIB/Samsung* will develop anti-TNF FoB’s in Europe:

http://finance.yahoo.com/news/biogen-idec-samsung-bioepis-announce-070000638.html

Although this PR doesn’t specify which anti-TNF FoB’s are under development, clinicaltrials.gov shows trials in progress for Remicade and Enbrel biosimilars.

See #msg-74411298 for information about pricing of these products.

Curiously, MRK is not mentioned in this PR even though it joined up with Samsung Bioepis in Feb 2013 (#msg-84781042).

*d/b/a Samsung Bioepis.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today